This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chao, D. L. Articles by Vaughan, T. L. Search for Related Content PubMed PubMed Citation Articles by Chao, D. L. Articles by Vaughan, T. L.

Mutagen Sensitivity and Neoplastic Progression in Patients with Barrett's Esophagus: A Prospective Analysis

Divisions of ¹ Human Biology and ² Public Health Sciences, Fred Hutchinson Cancer Research Center; Departments of ³ Epidemiology, ⁴ Pathology, ⁵ Genome Sciences, and ⁶ Medicine, University of Washington, Seattle, Washington; ⁷ Wistar Institute, Philadelphia, Pennsylvania; and ⁸ Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Dennis L. Chao, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, C1-157, Seattle, WA 98109. Phone: 206-667-4615; Fax: 206-667-6132; E-mail: dchao{at}fhcrc.org

Background: Defects in DNA damage recognition and repair have been associated with a wide variety of cancers. We conducted a prospective study to determine whether mutagen sensitivity, as determined by an in vitro assay, was associated with the future development of cancer in patients with Barrett's esophagus, which is associated with increased risk of progression to esophageal adenocarcinoma.

Methods: We measured sensitivity to bleomycin in peripheral blood lymphocytes in a cohort of 220 patients with Barrett's esophagus. We followed these patients for 1,230 person-years (range, 3 months to 10.1 years; median, 6.4 years), using development of cancer and aneuploidy as end points. A subset of these patients was evaluated for inactivation of tumor-suppressor genes CDKN2A/p16 and TP53 [by mutation and loss of heterozygosity (LOH)] in their Barrett's segments at the time of, or before, the bleomycin test, and the patients were stratified by CDKN2A/p16 and TP53 status in an analysis of mutagen sensitivity and progression.

Results: Bleomycin-sensitive patients were found to be at significantly greater risk of developing aneuploidy (adjusted hazard ratio, 3.71; 95% confidence interval, 1.44-9.53) and nonsignificantly greater risk of cancer (adjusted hazard ratio, 1.63; 95% confidence interval, 0.71-3.75). Among patients with detectable LOH at the TP53 locus (on chromosome 17p), increasing bleomycin sensitivity was associated with increased risk of developing cancer (P_trend < 0.001) and aneuploidy (P_trend = 0.005).

Conclusions: This study supports the hypothesis that sensitivity to mutagens increases the risk of neoplastic progression in persons with Barrett's esophagus, particularly those with 17p LOH including TP53. (Cancer Epidemiol Biomarkers Prev 2006;15(10):1935–40)

This article has been cited by other articles:

				F. Yousef, C. Cardwell, M. M. Cantwell, K. Galway, B. T. Johnston, and L. Murray The Incidence of Esophageal Cancer and High-Grade Dysplasia in Barrett's Esophagus: A Systematic Review and Meta-Analysis Am. J. Epidemiol., August 1, 2008; 168(3): 237 - 249. [Abstract] [Full Text] [PDF]

				X. Wu, J. Gu, and M. R. Spitz Mutagen Sensitivity: A Genetic Predisposition Factor for Cancer Cancer Res., April 15, 2007; 67(8): 3493 - 3495. [Abstract] [Full Text] [PDF]